Tilray Brands' Q3 results were disappointing, with revenues falling well short of expectations and significant cash burn leading to continued dilution. The company reduced its fiscal year revenue ...
Ernexa Therapeutics announced a 1-for-15 reverse stock split of its common shares, effective June 12, 2025, to meet Nasdaq's minimum bid price requirement of $1.00 for continued listing. This action ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback